The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A controlled, nonrandomized clinical research on chemotherapy combined with re-endostatin for stage IIB ostosarcoma.
Hairong Xu
No relevant relationships to disclose
Bin Li
No relevant relationships to disclose
Zhen Huang
No relevant relationships to disclose
Qing Zhang
No relevant relationships to disclose
Xiaohui Niu
No relevant relationships to disclose